BN 50739

platelet activating factor antagonist; structure given in first source

Also Known As:

BN-50739; tetrahydro-4,7,8,10 methyl-(chloro-2-phenyl)-6-((3,4-dimethoxyphenyl)thio)methylthiocarbonyl-9-pyrido(4',3'-4,5)thieno(3,2-f)triazolo-1,2,4(4,3-a)diazepine-1,4; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(2-((3,4-dimethoxyphenyl)thio)-1-thioxoethyl)-7,8,9,10-tetrahydro-1-methyl-

Networked: 21 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - BN 50739: 21
  - Azepines: 11
    - BN 50739: 21

Experts

1.	Dohi, Toshihiro: 2 articles (01/2014 - 10/2004)
2.	Morita, Katsuya: 2 articles (01/2014 - 10/2004)
3.	Kanematsu, Takashi: 1 article (01/2014)
4.	Kitayama, Tomoya: 1 article (01/2014)
5.	Motoyama, Naoyo: 1 article (01/2014)
6.	Shiraishi, Seiji: 1 article (01/2014)
7.	Uezono, Yasuhito: 1 article (01/2014)
8.	Dohi, T: 1 article (09/2013)
9.	Kanematsu, T: 1 article (09/2013)
10.	Kitayama, T: 1 article (09/2013)

Related Diseases

1.	Hyperalgesia 10/01/2004 - "Tactile allodynia induced by PAF was blocked by a PAF receptor antagonists, TCV-309, WEB 2086 and BN 50739. " 01/01/2014 - "Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. " 09/01/2013 - "PAF antagonists, TCV-309, BN 50739 and WEB 2086 by intravenous (i.v.) and oral administration have potent and long-lasting anti-allodynia action in mice neuropathic pain models. "
2.	Ventricular Fibrillation 09/01/1999 - "Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves an ischaemia-selective mechanism." 05/01/1991 - "BN 50739 was applied at concentrations of 10(-7), 10(-6), 10(-5) and 5 X 10(-5) M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined. "
3.	Ventricular Tachycardia 05/01/1991 - "Regional ischaemia triggered ventricular arrhythmias showing high incidence between 12 and 20 min with peak appearance at 16 min. BN 50739 induced dose dependent protection against ventricular tachycardia and fibrillation: incidences declined from their respective control values of 91% and 75% to 33% (p less than 0.05) and 8% (p less than 0.05) after exposure to 10(-5) M, and to 25% (p less than 0.05) and 8% (p less than 0.05) after exposure to 5 X 10(-5) M concentrations. " 05/01/1991 - "BN 50739 was applied at concentrations of 10(-7), 10(-6), 10(-5) and 5 X 10(-5) M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined. "
4.	Pain (Aches) 01/01/2014 - "Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. "
5.	Brain Ischemia (Cerebral Ischemia) 09/01/1997 - "Hyperglycemic damage to mitochondrial membranes during cerebral ischemia: amelioration by platelet-activating factor antagonist BN 50739." 05/01/1994 - "Effect of the platelet-activating factor antagonist BN 50739 and its diluents on mitochondrial respiration and membrane lipids during and following cerebral ischemia." 05/01/1994 - "The Pulsinelli-Brierley four-vessel occlusion model was used to study the effect of a synthetic platelet-activating factor antagonist, BN 50739, and its solvents, either dimethyl sulfoxide or hydroxypropyl-beta-cyclodextrin, on cerebral ischemia-reperfusion. "

Related Drugs and Biologics

1.	TCV 309
2.	WEB 2086 (apafant)
3.	Platelet Activating Factor
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Solvents
6.	Dimethyl Sulfoxide (DMSO)
7.	2-Hydroxypropyl-beta-cyclodextrin
8.	salicylhydroxamic acid (SHAM)
9.	Thromboxane B2
10.	Arachidonic Acid (Vitamin F)

Related Therapies and Procedures

1.	Ligation
2.	Intravenous Administration
3.	Lasers (Laser)
4.	Oral Administration